Zydus Lifesciences has launched REVAHALE™ (Revefenacin), India’s first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA). This new treatment option is designed for the maintenance of Chronic Obstructive Pulmonary Disease (COPD). REVAHALE™ offers sustained 24-hour bronchodilation through convenient nebulised delivery, addressing unmet needs in COPD management, particularly for patients with severe impairment or difficulty using handheld inhalers.
Zydus Lifesciences Launches REVAHALE™ for COPD Treatment
Zydus Lifesciences Limited announced today, August 10, 2026, the launch of REVAHALE™ (Revefenacin). This marks a significant development as it is India’s first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).
Innovating COPD Management
REVAHALE™ is positioned as the first and only LAMA in India offering once-daily dosing combined with nebulised administration. This novel approach aims to provide sustained 24-hour bronchodilation with a single daily dose. The therapy is developed to address key challenges faced by patients reliant on inhaler-dependent treatments, especially the elderly and those with severe respiratory conditions, offering improved drug delivery through a convenient nebulised platform compatible with standard jet nebulisers.
Clinical Efficacy and Safety
Clinical studies have indicated that Revefenacin delivers significant and sustained improvements in lung function for patients with moderate to very severe COPD. The drug is designed for lung-selective action to maximise bronchodilatory effects while minimising systemic exposure. The company highlights a favourable safety profile for the treatment.
About Zydus Lifesciences Limited
Zydus Lifesciences Ltd. is an innovation-driven global lifesciences company committed to empowering individuals to live healthier lives. The group discovers, develops, manufactures, and markets a wide range of healthcare therapies. With over 30,000 employees worldwide, including 1,500 scientists, Zydus is dedicated to unlocking new possibilities in lifesciences through quality healthcare solutions.
Source: BSE
